STXS vs UCFI
STXS: Stereotaxis provides advanced robotic magnetic navigation systems that enhance the precision, safety, and efficiency of minimally invasive endovascular and electrophysiology procedures. UCFI: A China-based provider of grain-based, biotech-enhanced health foods currently facing significant regulatory challenges and a Nasdaq trading suspension.
Side-by-side fundamentals
| Metric | STXS | UCFI | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $0.8626 | $5.51 | |
| Market cap | $86M | $288M | |
| Net margin FY2025, SEC XBRL | -66.8% | n/a | |
| Gross margin FY2025, SEC XBRL | +52.7% | n/a | |
| Operating margin FY2025, SEC XBRL | -68.3% | n/a | |
| ROE FY2025, SEC XBRL | -160.5% | n/a | |
| ROA | -41.4% | +1.9% | UCFI higher |
| Debt / equity | 0.00 | 0.13 | STXS lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +20.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +4.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.39 | 0.06 | |
| 1-year return as of 2026-10-30 close | -70.5% | +0.0% | UCFI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.